Letter to Shareholders from CEO Dr. Ryan Saadi

WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN).

Dear Shareholders,

As we continue executing on Tevogen’s long-term strategy to evolve into a sustainable, revenue-generating healthcare enterprise, I would like to provide an update regarding our ongoing strategic initiatives.

Over the past several months, we have been actively evaluating potential acquisitions designed to complement our existing immunotherapy and artificial intelligence platforms. If consummated, these transactions are expected to operate as subsidiaries of Tevogen resulting in positive cash flow generation and a return on invested capital over time.

Based on preliminary evaluations, the combined entities under consideration may generate aggregate annual revenues in excess of $50 million. While these discussions remain subject to customary due diligence, negotiation, and definitive agreements, we believe the opportunity aligns with our disciplined growth strategy.

Tevogen was built on the belief that innovation and affordability are not mutually exclusive. As we expand, we remain committed to disciplined capital allocation, operational efficiency, and long-term shareholder value creation.

We appreciate your continued trust and support as we pursue strategic initiatives intended to strengthen Tevogen’s financial foundation while advancing our mission of developing accessible immunotherapies.

Sincerely,

Dr. Ryan Saadi
Founder & Chief Executive Officer
Tevogen

About Tevogen

Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.

Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.

Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

Forward Looking Statements